Rybelsus is the brand name for a new oral medication used in the treatment of type 2 diabetes. The generic name is Semaglutide and this is the same molecule that has been previously only been available as an injection called Ozempic.
Ozempic and Victoza (Liraglutide) are small proteins called peptides and normally these are broken down in the gut and no longer work. The major innovation with Rybelsus is the engineering to allow it to be taken orally, not be broken down and yet still be effective.
The normal maximuum dose of injected Ozempic is 1mg whereas the maximum dose of Rybelsus is 14mg. The different doses suggest that a lot of Rybelsus is still broken down in the gut before being absorbed.
To read more about Ozemepic please see the following blog post What is Ozempic and how does it does it work.
Rybelsus comes in three different dosages;
The starting dose of Rybelsus is 3mg once daily for the first month (30 days). After this time, and if the person is able to tolerate the medication, the dose should be increased to 7mg daily.
If blood sugars are still high, the Rybelsus dose may be increased to 14mg once daily after at least 30 days on the 7mg dose. To avoid confusion it is not recommended that two 7mg Rybelsus tablets be taken to achieve a 14mg dose and instead the 14mg single tablet be taken.
Semaglutide is the synthetic version of a naturally occurring human hormone, called Glucagon-like peptide 1 or GLP-1 that has been modified so that it is less likely to be broken down and therefore has a longer duration of action.
Whether you have diabetes, or you don’t have diabetes, we all make GLP-1. It has become clear that GLP-1 is a really important hormone to help us regulate our blood sugar levels and probably our appetite and weight.
After we eat, GLP-1 is released from the small intestine.
GLP-1 has a number of actions in the body that improve blood sugar levels that include the following:
Rybelsus has a 94% similarity to human GLP-1. It is able to work in a similar way to our naturally occurring GLP-1 in the body and therefore has very similar effects including:
GLP-1 is a naturally occurring hormone found in all people. Rybelsus (Semaglutide) shares 94% of the same structure as human GLP-1, however is synthetically manufactured. Semaglutide has been structurally modified to prevent it from being broken down by an enzyme in the blood called dipeptidyl peptidase-4 or DPP-4.
Rybelsus, like other types of GLP-1 medications ( Ozempic, Trulicity,Victoza, Bydureon and Byetta) works by mimicing the body's natural GLP-1 hormone to respond to elevated levels of blood glucose, working when the body needs it.
Rybelsus is taken once daily and is the only oral GLP-1 tablet whereas Ozempic, is an injectable form of semaglutide and it is an example of a once weekly GLP-1. Another example of long acting GLP-1 is Trulicity (generic name Dulaglutide).
Drugs that block the action of DPP-4 are called DPP-4 inhibitors and these have been used in the treatment of type 2 diabetes for many years. By blockimg the enzyme that breaks down naturally occurring GLP-1 they increase amount of GLP-1 in the body by a small amouunt. (Dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus). Examples of DPP-4 inhibitors include:
If a person is taking a GLP-1 therapy they should NOT also be taking a DDP4 inhibitor.
There have been a number of PIONEER studies which have looked at how effective Rybelsus is compared to other medications, for example Liraglutide, in terms of weight loss and reduction in Hb A1c readings.
The PIONEER 4 (Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial) study conducted a trial with 711 adult participants, all with Type 2 Diabetes. There were four test groups: metformin alone, metformin plus Rybelsus 14mg, metformin plus liraglutide 1.8mg subcutaneous, and metformin plus placebo.
At week 26 of the trial, the study found that a proportion of the subjects (68%) in the metformin and Rybelsus 14mg group,achieved a Hb A1c of less than 7% compared to the metformin and liraglutide 1.8mg group.
The PIONEER 3 study (Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial), consisting of 1864 subjects, tested the effectiveness of Rybelsus to Januvia (another DPP-4 inhibitor). There were four test groups: metformin alone, metformin plus a sulfonylurea and then randomised into a group with either Rybelsus 7mg, Rybelsus 14mg, or Januvia 100mg.
Compared to the group taking Januvia 100mg, both the Rybelsus 7mg and Rybelsus 14mg groups had a higher proportion of patients who achieved a Hb A1c level of less than 7%. Compared to Januvia 100mg, 44% of patients in the Rybelsus 7mg group and 56% of patients in the Rybelsus 14mg group, were able to achieve a Hb A1c of less than 7%. Only 32% of patients in the Januvia group were able to achieve this result.
Did you know that Dr Sultan has a video to explain Hb A1c? If you would like to learn more about Hb A1c, as well assess your risk of developing diabetes complications, visit the Hb A1c (Haemoglobin A1C) Calculator page or click the image below.
In the same PIONEER 4 study, the researches examined the effect of Rybelsus on weight loss. At 26 weeks, it was found that the group of participants who were in the Rybelsus 14mg group, had a 42% greater weight reduction compared to the liraglutide 1.8 mg group. This was a weight loss of 4.4kg (9.7lbs) for the Rybelsus group compared to 3.1kg (6.8lbs) for the liraglutide group.
While Rybelsus is not promoted as being a weight loss drug, there are benefits for weightloss in people who have diabetes.
If you're overweight or obese, losing weight can make a huge difference. Having too much visceral fat (Visceral Fat Mass Has Stronger Associations with Diabetes and Prediabetes than Other Anthropometric Obesity Indicators among Korean Adults, Dysfunctional Adiposity and the Risk of Prediabetes and Type 2 Diabetes in Obese Adults), a type of fat that’s stored around our internal organs, is associated with an increased risk of developing other health conditions, not just type 2 diabetes! This includes heart disease, heart attacks, stroke, and bowel cancer.
If you have type 2 diabetes, it is recommended that you lose your excess weight. Even if you lose a small amount of weight, it can help to improve your blood glucose levels.
Rybelsus is an oral medication in the form of a tablet swallowed by mouth. It is important to take Rybelsus properly to ensure adequate absorption.
Rybelsus should be taken on an empty stomach, for example when you first wake up, with a sip of plain water (no more than 4oz or 120mL). It should be taken at least 30 minutes before a meal.
The absorption and effectiveness of Rybelsus can be impacted if not taken properly. Rybelsus should not be taken less than 30 minutes before eating, or taken with food and beverages other than water. Other medications may decrease the absorption of Rybelsus reduucing the effectiveness.
Waiting more than 30 minutes to eat after taking Rybelsus, may increase the absorption.
Do not split, crush or chew the Rybelsus tablet as it will interfere with the coating that stops the medication being broken down in the stomach. You should swallow Rybelsus whole.
After 30 minutes, you can eat, drink, or take other oral medications. Rybelsus works best if you if eat 30 to 60 minutes after taking Rybelsus.
Rybelsus is taken once per day, at least 30 minutes before a meal.
If you miss your dose of Rybelsus (oral Semaglutide), skip the missed dose and go back to your regular schedule of once per day.
Although Rybelsus (Semaglutide) is an effective medication for the treatment of type 2 diabetes, there are a number of side effects. Below is a list of the side effects of Rybelsus, and includes common side effects and serious side effects.
The most common side effects of Rybelsus (Semaglutide) oral tablets are:
Rybelsus (Semaglutide) may also cause more serious side effects including:
The simple answer is no, GLP-1s do not cause thyroid cancer in humans.
Early studies demonstrated that when rats were treated with a different GLP-1 therpy in high dose many developed a very rare and lethal thyroid cancer called medullary thyroid carcinoma. Rats have very high levels of GLP-1 receptors in their thyroids. These are not present in human thyroid cell.
The early concern that GLP-1 causes thyriod cancer has lead to extensive investiagtions and studies looking at this issues and to date there has been nothing to suggest a concern despite millions of people being treated with GLP-1 therapies around the world. It is not recommended to use GLP-1 therapies like Trulicity and Victoza (liraglutide) if there is a family history of medullary cell carcinoma of the thyroid or Multiple Endocrine Neoplasia Type 2 (MEN 2).
Rybelsus (Semaglutide) is designed to be used by people with type 2 diabetes. In combination with diet and exercise, Rybelsus can help to improve glycaemic control. It is not approved for use in people with type 1 diabetes, in children or in pregnancy.
Currently, Rybelsus (Semaglutide) is not recommended for pregnant women. Other types of medications are used to treat diabetes in pregnant women.
If you are taking Rybelsus and are planning to become pregnant, talk to your doctor about the best way to control your blood glucose.
If you have type 2 diabetes and are looking to start a family, it is recommended that prior to conception and throughout pregnancy, your blood glucose levels and HbA1c levels are kept as close as possible to the target goals. These goals may be set by your doctor.
Please see the following articles for more information and diabetes and pregnancy:
Rybelsus must be taken on an empty stomach and at least 30 minutes before your first meal or beverage. This is to ensure that Rybelsus is properly absorbed.
If you have type 2 diabetes, making lifestyle changes, for example exercising and eating a healthier diet, is very important.
For ideas on how to reduce the carb content of some of your favourite foods, the article How to reduce carbs in your diet has many great ideas that won’t leave you missing out on flavour.
Here are some key points to remember when storing your Rybelsus (oral Semaglutide):
The following drugs are all based on the GLP-1 or Exendine molecule:
For more information about different Diabetes Treatments, please follow the links below.